化合物 W146 TFA T41237

Product Introduction
Bioactivity


英文名: W146 TFA

描述: W146 TFA 是选择性 1-磷酸-鞘氨醇受体亚型 1 (S1PR1) 的拮抗剂，EC50值为 398 nM。

体外活性: W146 is a S1PR1 antagonist with a K i of ~70-80 nM [1]. W146 pretreatment significantly increases activated cleaved caspase-3 levels. The reduced apoptosis of EPCs induced by S1P is completely abolished after treatment with W146 [2]. Apoptosis Analysis [2] Cell Line: Endothelial progenitor cells (EPCs). Concentration: 10 μM. Incubation Time: 30 min before the addition of S1P. Result: Increases activated cleaved caspase-3 levels.

体内活性: W146 (5 mg/kg, ip, prior to AMD3100 administration) pre-treatment exhibits an approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony forming assays, compared to that in mice treated with AMD3100 alone [3] The W146-mediated augmentation of KSL-HSPC mobilization is specific, because pretreatment of mice with W140 is unable to produce any effect on AMD3100-stimulated KSL-HSPC mobilization. Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count in mice [3]. Animal Model: Mice (4-6-week-old) [3]. Dosage: 5 mg/kg. Administration: IP, 1 hour prior to AMD3100 (ADM) administration. Result: Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: W-146 TFA | W146 TFA

化合物 W146 TFA T41237信息由TargetMol中国为您提供，如您想了解更多关于化合物 W146 TFA T41237报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途